NCT01562626: Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

NCT01562626
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Other, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with presence or history of brain metastases
https://ClinicalTrials.gov/show/NCT01562626

Comments are closed.

Up ↑